Octreotate Lu-177 DOTA Tyr-3 - Advanced Accelerator Applications

Drug Profile

Octreotate Lu-177 DOTA Tyr-3 - Advanced Accelerator Applications

Alternative Names: 177Lu-[DOTA0,Tyr3]octreotate; 177Lu-DOTA0-Tyr3-Octreotate; 177Lu-DOTATATE; 177Lu-labelled somatostatin analog peptide; [Lu-177]-Dota-Tyr3-Octreotate; [Lu-177]-DOTATATE; Lu-DOTATATE; Lutate; Lutathera; Lutetium (177Lu) oxodotreotide; Lutetium Lu 177 dotatate

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioSynthema
  • Developer Advanced Accelerator Applications; Centre Hospitalier Universitaire de Quebec; FUJIFILM Pharma; National Cancer Institute (USA)
  • Class Antineoplastics; Peptides; Radiopharmaceuticals
  • Mechanism of Action Somatostatin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Neuroendocrine tumours
  • Phase II Pheochromocytoma

Most Recent Events

  • 29 Sep 2017 Registered for Neuroendocrine tumours (Inoperable/Unresectable, Metastatic disease) in Norway, Iceland, Liechtenstein, European Union (IM)
  • 29 Sep 2017 Updated efficacy data from a phase III NETTER-1 trial in Neuroendocrine tumours released by Advanced Accelerator Applications
  • 06 Sep 2017 Phase I clinical trials in Neuroendocrine tumours (Inoperable/Unresectable) in Japan (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top